CONSOLIDATED STATEMENT OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT (USD $) In Thousands, except Share data	Total USD ($)	Series A 12% Convertible Preferred Stock USD ($)	Series B-2 12% redeemable convertible preferred stock USD ($)	Series C super dividend convertible preferred stock USD ($)	Series B Preferred Stock USD ($)	Transaction 01 Series B-1 12% Redeemable Convertible Preferred Stock USD ($)	Transaction 02 Series B-2 12% redeemable convertible preferred stock USD ($)	Transaction 03 Series B-2 12% redeemable convertible preferred stock USD ($)	Issuance During Period 1st USD ($)	Issuance During Period 1st Notes Payable USD ($)	Issuance During Period 1st Convertible Notes Payable USD ($)	Issuance During Period 1st Private Placement Series A 12% Convertible Preferred Stock USD ($)	Issuance During Period 1st Employee Stock Option USD ($)	Issuance During Period 2nd USD ($)	Issuance During Period 2nd Series B-1 12% Redeemable Convertible Preferred Stock USD ($)	Issuance During Period 2nd Convertible Notes Payable USD ($)	Issuance During Period 2nd Cash USD ($)	Issuance During Period 2nd Private Placement USD ($)	Issuance During Period 3rd USD ($)	Issuance During Period 3rd Series B-2 12% redeemable convertible preferred stock USD ($)	Issuance During Period 3rd Private Placement USD ($)	Issuance During Period 4th Series C super dividend convertible preferred stock USD ($)	Issuance During Period 4th Notes Payable USD ($)	Issuance During Period 5th Private Placement USD ($)	Issuance During Period 6th Consulting Services USD ($)	Issuance During Period 7th Accrued Liabilities USD ($)	Issuance During Period 8th Private Placement USD ($)	Issuance During Period 9th Private Placement USD ($)	Issuance During Period 10th Private Placement USD ($)	Issuance During Period 11th Private Placement USD ($)	Issuance During Period 12th Cash USD ($)	Period 1 Series B-2 12% redeemable convertible preferred stock USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock Series B Preferred Stock USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock Transaction 01 USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock Issuance During Period 2nd USD ($)	Series B-2 12% redeemable convertible preferred stock USD ($)	Series B-2 12% redeemable convertible preferred stock USD ($)	Series B-2 12% redeemable convertible preferred stock Series B Preferred Stock USD ($)	Series B-2 12% redeemable convertible preferred stock Transaction 02 USD ($)	Series B-2 12% redeemable convertible preferred stock Transaction 03 USD ($)	Series B-2 12% redeemable convertible preferred stock Issuance During Period 3rd USD ($)	Series B-2 12% redeemable convertible preferred stock Period 1 USD ($)	Series C super dividend convertible preferred stock USD ($)	Series C super dividend convertible preferred stock USD ($)	Series C super dividend convertible preferred stock Issuance During Period 4th USD ($)	Series A 12% Convertible Preferred Stock USD ($)	Series A 12% Convertible Preferred Stock USD ($)	Series A 12% Convertible Preferred Stock Issuance During Period 1st Private Placement USD ($)	Series A 12% Convertible Preferred Stock Issuance During Period 14th USD ($)	Common Stock USD ($)	Common Stock Series A 12% Convertible Preferred Stock	Common Stock Series B-1 12% Redeemable Convertible Preferred Stock	Common Stock Series B-2 12% redeemable convertible preferred stock	Common Stock Series C super dividend convertible preferred stock	Common Stock Issuance During Period 1st	Common Stock Issuance During Period 1st Notes Payable	Common Stock Issuance During Period 1st Employee Stock Option	Common Stock Issuance During Period 2nd USD ($)	Common Stock Issuance During Period 2nd Cash	Common Stock Issuance During Period 3rd USD ($)	Common Stock Issuance During Period 3rd Private Placement USD ($)	Common Stock Issuance During Period 4th Series C super dividend convertible preferred stock	Common Stock Issuance During Period 4th Notes Payable	Common Stock Issuance During Period 5th Private Placement	Common Stock Issuance During Period 6th Consulting Services	Common Stock Issuance During Period 7th Accrued Liabilities	Common Stock Issuance During Period 8th Private Placement USD ($)	Common Stock Issuance During Period 9th Private Placement	Common Stock Issuance During Period 10th Private Placement	Common Stock Issuance During Period 11th Private Placement USD ($)	Common Stock Issuance During Period 12th Cash USD ($)	Common Stock Issuance During Period 14th Series A 12% Convertible Preferred Stock	Additional Paid-In Capital USD ($)	Additional Paid-In Capital Series A 12% Convertible Preferred Stock USD ($)	Additional Paid-In Capital Series B-1 12% Redeemable Convertible Preferred Stock USD ($)	Additional Paid-In Capital Series B-2 12% redeemable convertible preferred stock USD ($)	Additional Paid-In Capital Series C super dividend convertible preferred stock USD ($)	Additional Paid-In Capital Issuance During Period 1st USD ($)	Additional Paid-In Capital Issuance During Period 1st Notes Payable USD ($)	Additional Paid-In Capital Issuance During Period 1st Convertible Notes Payable USD ($)	Additional Paid-In Capital Issuance During Period 1st Employee Stock Option USD ($)	Additional Paid-In Capital Issuance During Period 2nd USD ($)	Additional Paid-In Capital Issuance During Period 2nd Series B-1 12% Redeemable Convertible Preferred Stock USD ($)	Additional Paid-In Capital Issuance During Period 2nd Convertible Notes Payable USD ($)	Additional Paid-In Capital Issuance During Period 2nd Cash USD ($)	Additional Paid-In Capital Issuance During Period 2nd Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 3rd USD ($)	Additional Paid-In Capital Issuance During Period 3rd Series B-2 12% redeemable convertible preferred stock USD ($)	Additional Paid-In Capital Issuance During Period 3rd Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 4th Series C super dividend convertible preferred stock USD ($)	Additional Paid-In Capital Issuance During Period 4th Notes Payable USD ($)	Additional Paid-In Capital Issuance During Period 5th Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 6th Consulting Services USD ($)	Additional Paid-In Capital Issuance During Period 7th Accrued Liabilities USD ($)	Additional Paid-In Capital Issuance During Period 8th Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 9th Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 10th Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 11th Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 12th Cash USD ($)	Additional Paid-In Capital Period 1 Series B-2 12% redeemable convertible preferred stock USD ($)	Additional Paid-In Capital Issuance During Period 14th Series A 12% Convertible Preferred Stock USD ($)	Deficit Accumulated During the Development Stage USD ($)	Deficit Accumulated During the Development Stage Series A 12% Convertible Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Series B-1 12% Redeemable Convertible Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Series B-2 12% redeemable convertible preferred stock USD ($)	Deficit Accumulated During the Development Stage Series C super dividend convertible preferred stock USD ($)	Deficit Accumulated During the Development Stage Series B Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Transaction 01 Series B-1 12% Redeemable Convertible Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Transaction 02 Series B-2 12% redeemable convertible preferred stock USD ($)	Deficit Accumulated During the Development Stage Transaction 03 Series B-2 12% redeemable convertible preferred stock USD ($)
Beginning Balance at Jul. 09, 2000
Issuance of founders shares July 10, 2000 (in shares)																																																			2,059,112
Issuance of founders shares July 10, 2000	$ 9																																																		$ 2																							$ 7
Beneficial conversion feature	222																															1,016											(1,016)																															222																											1,016
Issuance of common stock and beneficial conversion feature related to convertible note in 2001 (in shares)																																																			110,054
Issuance of common stock and beneficial conversion feature related to convertible note in 2001	1,036																																																																									1,036
Issuance of common stock in connection with reverse merger of Pro-Pharmaceuticals-NV in 2001 (in shares)																																																			203,649
Issuance of common stock in connection with reverse merger of Pro-Pharmaceuticals-NV in 2001	107																																																																									107
Issuance of common stock (in shares)																																																		(180,000)							99,705			31,000		537,227		17,647	181,334	2,042	33,618	399,917	219,096	206,019	333,334	1,250,000	30,000
Issuance of common stock										1,126							602				2,861		290	1,070	12	302	4,410	1,319	1,898	490	1,044																			(72)												1						1			1	1								1,126						602				2,860		290	1,070	12	302	4,409	1,319	1,898	489	1,043		72
Issuance of Common Stock Warrants											503					236		261	20																																																														503				236		261	20
Issuance of common stock and warrants (net of issuance costs of $17) in 2001 (in shares)																																																			114,884
Issuance of common stock and warrants (net of issuance costs of $17) in 2001	2,221																																																																									2,221
Receipt of subscription receivable	150																																																																									150
Reclassification of Warrant Liabilities	3,193																																																																									3,193
Deferred compensation relating to issuance of stock options	455																																																																									455
Stock compensation expense related to fair market revaluation	157																																																																									157
Stock-based compensation expense	8,869																																																																									8,869
Accretion of redeemable convertible preferred stock						(1,286)	(1,900)	(629)																											1,286					1,900	629																																																																				(1,286)	(1,900)	(629)
Issuance of redeemable convertible preferred stock (in shares)																																				900,000						2,100,000				225			1,742,500
Issuance of redeemable convertible preferred stock												704			1,105					2,761																395						1,174				2,203			704																																			1,105					2,761
Convertible preferred stock dividend (in shares)																																																				129,080	203,223	345,694	17,066
Convertible preferred stock dividend		(47)		(33)																																																																							772	810	1,500	97																										(819)	(810)	(1,500)	(130)
Issuance of restricted common stock (in shares)																																																			454,167
Issuance of restricted common stock																																																			1																							(1)
Issuance of common stock upon exercise of warrants (in shares)																																																			3,407,393
Issuance of common stock upon exercise of warrants	14,307																																																		3																							14,304
Issuance of common stock upon exercise of options (in shares)																																																										2,772	347,107
Issuance of common stock upon exercise of options													74	362																																													1																							74	361
Stock issued in conversion of convertible securities (in shares)																																														(5)										79,367			1,227,972		867,558		8,334
Stock issued in conversion of convertible securities									1,745					3,948					5,330			49																								(49)													1		1																		1,745				3,947					5,329			49
Stock compensation related to the issuance of common shares (in shares)																																																			1,167
Stock compensation related to the issuance of common shares	27																																																																									27
Cumulative effect of adoption of new accounting principle	(204)																																																																									(458)																													254
Net loss	(62,317)																																																																																																						(62,317)
Ending Balance at Dec. 31, 2011	(2,125)																																1,681											2,154			632				13																							66,367																													(69,137)
Ending Balance (in shares) at Dec. 31, 2011																																	900,000											220			1,562,500				12,919,538
Beginning Balance at Dec. 31, 2009	(4,467)																																1,270				644										664				9																							42,575																													(47,715)
Beginning Balance (in shares) at Dec. 31, 2009																																	900,000				1,330,000										1,642,500				8,623,687
Beneficial conversion feature			388																																			(388)																																							388
Stock-based compensation expense	1,942																																																																									1,942
Accretion of redeemable convertible preferred stock					(1,730)																													394					1,336																																																																					(1,730)
Accretion of beneficial conversion feature for Series B-2	(448)																																				448																																																																		(448)
Issuance of redeemable convertible preferred stock (in shares)																																						770,000							212
Issuance of redeemable convertible preferred stock			1,029																																			434							2,073																																1,029
Convertible preferred stock dividend (in shares)																																																				32,681	76,096	160,725
Convertible preferred stock dividend		4																																																																									196	228	482																											(192)	(228)	(482)
Issuance of restricted common stock (in shares)																																																			16,667
Issuance of common stock upon exercise of warrants (in shares)																																																			1,636,011
Issuance of common stock upon exercise of warrants	7,089																																																		2																							7,087
Issuance of common stock upon exercise of options (in shares)																																																			97,334
Issuance of common stock upon exercise of options	128																																																																									128
Stock issued in conversion of convertible securities (in shares)																																																(50,000)				8,334
Stock issued in conversion of convertible securities																																																(20)																											20
Net loss	(5,629)																																																																																																						(5,629)
Ending Balance at Dec. 31, 2010	(1,694)																																1,664				2,474							2,073			644				11																							54,075																													(56,424)
Ending Balance (in shares) at Dec. 31, 2010																																	900,000				2,100,000							212			1,592,500				10,651,535
Stock-based compensation expense	3,245																																																																									3,245
Accretion of redeemable convertible preferred stock					(176)																													17					159																																																																					(176)
Accretion of beneficial conversion feature for Series B-2	(54)																																				54																																																																		(54)
Issuance of redeemable convertible preferred stock (in shares)																																													13
Issuance of redeemable convertible preferred stock																																													130
Convertible preferred stock dividend (in shares)																																																				30,321	59,588	139,037	17,066
Convertible preferred stock dividend		1		(33)																																																																							180	378	881	97																										(179)	(378)	(881)	(130)
Issuance of restricted common stock (in shares)																																																			20,834
Issuance of common stock upon exercise of warrants (in shares)																																																			1,771,383
Issuance of common stock upon exercise of warrants	7,218																																																		2																							7,216
Issuance of common stock upon exercise of options (in shares)																																																			216,440
Issuance of common stock upon exercise of options	234																																																																									234
Stock issued in conversion of convertible securities (in shares)																																													(5)			(30,000)				5,000			8,334
Stock issued in conversion of convertible securities				49																																									(49)			(12)																											12			49
Net loss	(10,915)																																																																																																						(10,915)
Ending Balance at Dec. 31, 2011	$ (2,125)																																$ 1,681				$ 2,687							$ 2,154			$ 632				$ 13																							$ 66,367																													$ (69,137)
Ending Balance (in shares) at Dec. 31, 2011																																	900,000				2,100,000							220			1,562,500				12,919,538